(0.33%) 5 116.56 points
(0.32%) 38 363 points
(0.37%) 15 986 points
(-0.97%) $83.04
(5.25%) $2.02
(0.32%) $2 354.70
(0.49%) $27.67
(4.10%) $959.95
(-0.27%) $0.932
(-0.46%) $10.97
(-0.58%) $0.796
(1.66%) $93.40
@ $25.11
発行日: 15 2月 2024 @ 05:41
リターン: 26.28%
前回のシグナル: 2月 14 - 05:43
前回のシグナル:
リターン: 3.95 %
Live Chart Being Loaded With Signals
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders...
Stats | |
---|---|
本日の出来高 | 780 885 |
平均出来高 | 877 920 |
時価総額 | 2.43B |
EPS | $0 ( 2024-04-25 ) |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -3.79 |
ATR14 | $0.0580 (0.18%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-19 | Klein Matthew B. | Sell | 3 361 | Common Stock |
2024-04-17 | Pauwels Eric | Sell | 787 | Common Stock |
2024-04-17 | Klein Matthew B. | Sell | 1 307 | Common Stock |
2024-04-02 | Golden Lee Scott | Sell | 526 | Common Stock |
2024-02-15 | Utter Christine Marie | Buy | 2 900 | Common Stock |
INSIDER POWER |
---|
73.37 |
Last 98 transactions |
Buy: 1 039 114 | Sell: 204 439 |
ボリューム 相関
PTC Therapeutics Inc 相関
10 最も負の相関 |
---|
知っていましたか?
相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関(1つの変数が増加すると、もう一方は減少する)、1は完全な正の相関(1つの変数が増加すると、もう一方も増加する)、0は相関がないことを示します(変数間に関係がない)。
相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。
PTC Therapeutics Inc 相関 - 通貨/商品
PTC Therapeutics Inc 財務諸表
Annual | 2023 |
収益: | $937.82M |
総利益: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2023 |
収益: | $937.82M |
総利益: | $649.70M (69.28 %) |
EPS: | $-8.37 |
FY | 2022 |
収益: | $698.80M |
総利益: | $654.12M (93.61 %) |
EPS: | $-7.79 |
FY | 2021 |
収益: | $538.59M |
総利益: | $506.27M (94.00 %) |
EPS: | $-7.26 |
Financial Reports:
No articles found.
PTC Therapeutics Inc
PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil. The company's splicing platform includes PTC518, which is being developed for the treatment of Huntington's disease. PTC Therapeutics, Inc. has collaborations with F. Hoffman-La Roche Ltd and Hoffman-La Roche Inc., as well as the Spinal Muscular Atrophy Foundation to advance drug discovery and development research in regenerative medicine; and Akcea Therapeutics, Inc. to commercialize Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean. PTC Therapeutics, Inc. was incorporated in 1998 and is headquartered in South Plainfield, New Jersey.
について ライブシグナル
このページで提示されるライブシグナルは、NA を買う時や売る時を判断するのに役立ちます。シグナルには1分以上の遅延があります。市場シグナルには誤りやミスの可能性があるため、ライブ取引シグナルは決定的ではなく、getagraph.comはこれらのシグナルに基づく任意の行動について責任を負いません。詳細については、利用規約で説明されているように、技術分析指標に基づいています。